GlassScriptPhysician profile
Lian T Bach
NPI 1144490962
$2,309.91
in general payments reported to CMS, 2019-2025
19 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $156 · 2021: $96.40 · 2022: $182 · 2023: $138 · 2024: $274 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $888 · Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $887.89 |
| Food and Beverage | $557.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $887.89 | 2025 | Spikevax |
| Astrazeneca Pharmaceuticals LP | $430.41 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $206.13 | 2019-2022 | |
| Novo Nordisk INC | $163.43 | 2019-2024 | Rybelsus, Ozempic |
| Nevro Corp. | $102.95 | 2022 | |
| Gilead Sciences, INC. | $67.31 | 2019-2024 | |
| Allergan, INC. | $59.01 | 2019-2020 | |
| Abbvie INC. | $54.98 | 2022-2023 | Qulipta |
| Glaxosmithkline, LLC. | $48.14 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Teva Pharmaceuticals USA, INC. | $44.01 | 2019 | |
| Pfizer INC. | $43.97 | 2019-2022 | |
| Lilly USA, LLC | $43.94 | 2019-2025 | Mounjaro |
| Inari Medical, INC. | $31.92 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $29.67 | 2023 | |
| Sanofi Pasteur INC. | $27.06 | 2019-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.06 | 2019 | |
| Merck Sharp & Dohme LLC | $17.63 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lian Bach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.